NCT06840899

CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury

Cannabinoid Modulation for Neurogenic Lower Urinary Tract Dysfunction in Spinal Cord Injury

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: University of Wisconsin, Madison · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this feasibility study is to learn whether Cannabidiol (CBD) can improve urinary incontinence and other symptoms in people with recent spinal cord injury (SCI). Participants will take Epidiolex (purified CBD) for 90 days

Detailed description

This pilot study assesses the feasibility of using 100mg of twice daily cannabidiol (Epidiolex) in adult spinal cord injury with neurogenic lower urinary tract dysfunction following resolution of spinal shock.

Conditions

• Supra-sacral Spinal Cord Injury
• Spinal Cord Injury
• Urinary Incontinence

Interventions

Type	Name	Description
DRUG	CBD	Twice daily 100mg cannabidiol (CBD)

Timeline

• Start date: 2026-02-13
• Primary completion: 2027-05-01
• Completion: 2027-05-01
• First posted: 2025-02-21
• Last updated: 2026-03-04

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study